Category: Corona Virus Vaccine

Page 36«..1020..35363738..5060..»

COVID-19 Vaccine Shows Reduced Effect in Patients With RA Receiving DMARDs – Drug Topics

January 3, 2024

Patients with rheumatoid arthritis (RA) receiving disease-modifying antirheumatic drugs (DMARDs) showed reduced immune responses to the COVID-19 vaccine compared with controls, in a recent study published in Journal of Rheumatic Diseases.1

Patients with RA carry increased risks for developing infections, including COVID-19. Since the introduction of the COVID-19 vaccine, additional concerns have emerged regarding the potential of vaccine-induced RA flare-ups or other forms of autoimmune or inflammatory phenomena. As DMARDs have provided benefits to patients with RA, such as reducing and modulating inflammatory and immune system responses, researchers conducted a cross-sectional study to investigate lacking data on COVID-19 vaccine responses in patients with RA receiving DMARDs.

From May 2022 to April 2023, patients with RA receiving DMARDs were evaluated at 2 tertiary care centers. Patients with seropositive as well as seronegative status were accepted. Investigators gathered data on individual COVID-19 infection and vaccination histories, prescribed and administered medications (DMARDs), as well as scaling on the Disease Activity Score-28 (DAS28). Blood samples of 10 mL were also taken for examination of erythrocyte sedimentation rate (ESR), complete blood count, C-reactive protein (CRP), liver and renal function, and neutralizing antibodies for COVID-19.

In total, 103 patients with RA were recruited and compared with 185 controls. In the RA group, 42% of individuals had comorbiditiesmost commonly, hypothyroidism (16.5%). The RA group was also vaccinated against COVID-19 at rates of 79.6% compared with 91.3% in the controls. No controls had a history of COVID-19 infection, but 13.6% of patients with RA did. Most of the patients with RA were identified as having low disease activity (mean DAS28 of 2.9).

Researchers observed that patients with RA had overall higher mean levels of ESR and elevated IL-6 compared with controls (ESR: 26.0 vs 19.2; P = .0004; IL-6: 15.8 vs 3.7; P < .0001).

Each group registered positive results for antispike antibodies; this was significantly higher in controls compared with patients with RA (95.9 vs 89.5; P < .0001). Interestingly, in patients with RA, age was positively correlated with levels of anti-spike antibodies (P = .0015), but this was not significant in controls. Antibody status in groups using different amounts of DMARDs were statistically significant, especially between individuals on a 3-drug regimen compared with those on a single-drug regimen of hydroxychloroquine alone (P = .0192). The authors noted that neither the presence of comorbidities nor the type of COVID-19 vaccine received, prior infection, or booster status had a statistically significant effect on antibody concentration.

The authors noted the positive takeaway that patients with RA exhibited robust immune responses following their COVID-19 vaccination, although this response was reduced compared with controls. They theorized that this could be due to disease-related or immunosuppressive treatment factors, and advocated for future research to be conducted to analyze responses following second vaccination doses.

This article originally appeared in AJMC.

See the article here:

COVID-19 Vaccine Shows Reduced Effect in Patients With RA Receiving DMARDs - Drug Topics

Holiday flu and COVID-19 cases slam NJ | Video – NJ Spotlight News

January 3, 2024

Request blocked. We can't connect to the server for this app or website at this time. There might be too much traffic or a configuration error. Try again later, or contact the app or website owner. If you provide content to customers through CloudFront, you can find steps to troubleshoot and help prevent this error by reviewing the CloudFront documentation. Generated by cloudfront (CloudFront)Request ID: 9HN8tCfeL_uOmKCnOu2XqqqeluHEFkyG-2x6lW2mmZz07-HzzjHejA==

Visit link:

Holiday flu and COVID-19 cases slam NJ | Video - NJ Spotlight News

Top in ID: Paxlovid unlikely contributes to COVID-19 rebound; a roundup of 2023 guidelines – Healio

January 3, 2024

January 02, 2024

1 min read

Add topic to email alerts

Receive an email when new articles are posted on

Back to Healio

Two separate analyses of studies and trials suggest that COVID-19 rebound is not linked to Paxlovid or other antiviral drugs.

The findings contradict other studies that indicated a higher frequency of COVID-19 rebound among people treated with Paxlovid (nirmatrelvir/ritonavir, Pfizer).

Rebound is typically described as a recurrence of symptoms after recovery or a new positive viral test after testing negative, Pragna Patel, MD, MPH, DRM&H, chief medical officer in the Coronavirus and Other Respiratory Viruses division of the CDCs National Center for Immunization and Respiratory Diseases, told Healio. We found that there was no consistent association between treatment for COVID-19 and COVID-19 rebound. Also, we found that COVID-19 rebound can happen among patients whether they received antiviral treatments or not.

It was the top story in infectious disease last week.

Another top story was a collection of articles about ID-related guidelines released in 2023, including recommendations on sexually transmitted disease prevention, diabetic foot infections and more.

Read these and more top stories in infectious disease below:

Paxlovid unlikely to contribute to COVID-19 rebound

SARS-CoV-2 rebound risk is more likely related to the individual person, rather than reinfection or resistance to treatment such as Paxlovid, according to two studies. Read more.

Doxy-PEP, diabetic foot infections and more: The year in ID guidelines

New guidance was published in 2023 for STD prevention, diabetic foot infections, infective endocarditis and more. Read more.

COVAX to end as COVID-19 vaccines move to routine immunization programs

COVAX, the multinational program launched in 2020 to deliver COVID-19 vaccines to low- and lower-middle income countries, will end on Dec. 31, 2023, as the vaccines shift to routine immunization programs. Read more.

Pneumonia, candidiasis and more: The non-vaccine approvals of 2023

The FDA in 2023 approved treatments for several hospital-associated infections and fully approved a long-used COVID-19 medication, among other non-vaccine-related regulatory decisions. Read more.

Developments in hepatitis care: New CDC recommendations and more

As viral hepatitis continues to be a major health concern in the infectious disease field, recent research has highlighted the importance of testing and treatment. Read more.

Add topic to email alerts

Receive an email when new articles are posted on

Back to Healio

See the rest here:

Top in ID: Paxlovid unlikely contributes to COVID-19 rebound; a roundup of 2023 guidelines - Healio

Effects of antivirals on patients with COVID-19 breakthrough – BMC Infectious Diseases – BMC Infectious Diseases

January 3, 2024

Study design and participants

A retrospective cohort study was conducted at Nhan Dan Gia Dinh (NDGD) Hospital, a general tertiary hospital in Vietnam. Participant recruitment was taken by screening a sampling frame of patients under the management of NDGD Hospital from January 1, 2021, to January 31, 2022. We included patients who: (1) were 18 years old; (2) were fully vaccinated against COVID-19 before infection (received at least 2 doses, either homologous or heterologous, of the following vaccines: BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna), AZD1222 (AstraZeneca), or BBIBP-CorV (Sinopharm), at least 2 weeks before getting first COVID-19); (3) had a confirmative diagnosis of COVID-19 (positive to either real-time polymerase chain reaction test or rapid antigen test with typical symptom(s) of COVID-19); and (4) agreed to participate. Patients were excluded if they: (1) were pregnant or breastfeeding; (2) were severely or critically ill before treatment (based on the clinical spectrum proposed by the NIH [13]); (3) were moderately or severely immunocompromised (immunosuppressive medications, moderate or severe primary immunodeficiency, advanced or untreated human immunodeficiency virus infection, active cancer treatment, or white blood cell count<4109/L); (4) were renally impaired (estimated glomerular filtration rate<30 mL/minutes/1.73 m2); or (5) were hepatically impaired (ChildPugh class B or C).

We followed the participants until March 31, 2022, or until they left the study. We reported this study in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement (Supplementary Checklist, available in the Supplementary File).

Two groups were investigated, of which patients were given: (1) standard of care (SoC, control group) or (2) standard of care plus antiviral (SoC+antiviral). In our study setting, SoC referred to treatment with appropriate medications (excluding antivirals) and supportive care that aligned with the guidelines of Vietnams Ministry of Health [14], WHO [11, 15], IDSA [12], and NIH [13]. Antivirals included remdesivir, molnupiravir, and favipiravir. Remdesivir was given by intravenous infusion to hospitalized patients, with 200mg on the first day and 100mg on the next 4 days. Molnupiravir was taken orally, with 800mg twice daily for 5 days. Favipiravir was also an oral antiviral with dosage of 1,600mg twice daily on the first day and 600mg twice daily on the next days (duration of 57 days).

The primary outcome was residual respiratory symptoms of COVID-19 breakthrough (including but not be limited to cough, dyspnea/shortness of breath/difficulty breathing, congestion, sore throat, loss of smell), measured in frequency. Based on our pilot data, the proposed timeframe cut-off to classify residual symptoms in COVID-19 breakthrough was 7 days. Thus, patients having respiratory symptoms after day 7 (from the day with first symptoms or diagnosis, whichever happened first) were counted towards the primary outcome. As these participants were under the management of NDGD Hospital, they were encouraged to self-report symptoms of COVID-19 every 12 days until resolution using MyCap platform [16]. For data collection, patients without self-reported records were contacted to retrieve the this outcome.

The secondary outcome was long COVID-19 [17,18,19], measured in frequency. This was diagnosed by specialized physicians in COVID-19 at NDGD Hospital using the guideline of the National Institute for Health and Care Excellence [19]. Following that, long COVID-19 includes ongoing symptomatic COVID-19 (signs and symptoms of COVID-19 from 4 weeks up to 12 weeks) and post-COVID-19 syndrome (signs and symptoms that develop during or after an infection consistent with COVID19, continue for more than 12 weeks and are not explained by an alternative diagnosis) [19]. We collected these data by screening patient health records for long COVID-19 diagnosis.

We calculated the sample size using the online website Power and Sample Size [20], with type I error rate () of 5%, power (1 - ) of 80%, and a sampling ratio of 1:1. Following the findings of Bergwerk et al., 31% of infected healthcare workers had residual symptoms 14 days after diagnosis [21]. Given that our study was conducted on the general population with a 7-day cut-off, we estimated the primary outcome could be found in at least 41% of the patients. For antivirals to be considered effective against COVID-19 breakthrough in low and middle-income countries like Vietnam, we expected a reduction of at least 50% in the primary outcome, resulting in a minimum sample size of 144 patients. Thus, we decided to recruit 150 patients.

Considering our study setting, the following factors were identified as potential confounders: gender (female/male), age (in years), weight (in kg), height (in cm), comorbidities, and concurrent medications. To avoid overadjustment bias, we excluded medications for comorbidities, keeping only those that were used for COVID-19 treatment.

We removed observations that were missing or lost to follow-up from analysis. We presented demographic and baseline data as mean with standard deviation for continuous variables or as frequency with percentage for categorical variables. Incidence rates (using Poisson regression) and odds ratio (OR, using logistic regression) were given with 95% confidence intervals (95% CI). As there were 3 nationally approved antivirals for COVID-19 in Vietnam during this study timeframe (remdesivir, molnupiravir, and favipiravir), effect estimates might be biased by favipiravir due to its lack of evidence. To test the robustness of our findings, we conducted a sensitivity analysis by removing observations with favipiravir use. Since antivirals were primarily recommended for high-risk patients, we also wanted to explore these medications effects on both outcomes with a priori subgroup analysis. The subgroups were pre-specified based on the following variables: gender (male/female), age (<65/ 65), comorbidities (yes/no), and corticosteroid use (yes/no). This subgroup analysis was considered exploratory to generate new hypotheses (if available), so we did not attempt to adjust for multiplicity. All statistical hypotheses were tested with a confidence level of 95%. We performed all analyses using R software (version 4.2.1, R Foundation for Statistical Computing, Vienna, Austria).

This study was approved by the Institutional Review Board of NDGD Hospital, Ho Chi Minh City, Vietnam, under approval number 85-2021/CN-HDDD. All recruited participants gave their informed consent.

See the original post here:

Effects of antivirals on patients with COVID-19 breakthrough - BMC Infectious Diseases - BMC Infectious Diseases

Navigating Novel Uncertainties of COVID-19: The Rise of the JN.1 Variant – Cureus

January 3, 2024

Specialty

Please choose I'm not a medical professional. Allergy and Immunology Anatomy Anesthesiology Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health Family Medicine Forensic Medicine Gastroenterology General Practice Genetics Geriatrics Health Policy Hematology HIV/AIDS Hospital-based Medicine I'm not a medical professional. Infectious Disease Integrative/Complementary Medicine Internal Medicine Internal Medicine-Pediatrics Medical Education and Simulation Medical Physics Medical Student Nephrology Neurological Surgery Neurology Nuclear Medicine Nutrition Obstetrics and Gynecology Occupational Health Oncology Ophthalmology Optometry Oral Medicine Orthopaedics Osteopathic Medicine Otolaryngology Pain Management Palliative Care Pathology Pediatrics Pediatric Surgery Physical Medicine and Rehabilitation Plastic Surgery Podiatry Preventive Medicine Psychiatry Psychology Pulmonology Radiation Oncology Radiology Rheumatology Substance Use and Addiction Surgery Therapeutics Trauma Urology Miscellaneous

View original post here:

Navigating Novel Uncertainties of COVID-19: The Rise of the JN.1 Variant - Cureus

COVAX to end as COVID-19 vaccines move to routine immunization programs – Healio

January 3, 2024

December 28, 2023

2 min read

Add topic to email alerts

Receive an email when new articles are posted on

Back to Healio

COVAX, the multinational program launched in 2020 to deliver COVID-19 vaccines to low- and lower-middle income countries, will end on Dec. 31, 2023, as the vaccines shift to routine immunization programs.

The program has been jointly led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance (GAVI), UNICEF and WHO, which raised $2 billion to procure vaccines and delivered its first vaccination in a low-income nation in January 2021, 39 days after the vaccines had become available.

COVAX has delivered roughly 2 billion COVID-19 vaccine doses to 146 nations and is estimated to have prevented the deaths of at least 2.7 million people, achieving a two-dose coverage of 57% of people in lower-income nations, according to a joint press release from the four organizations.

Millions of people are alive today who would not have been here without COVAX. Those averted deaths mean mothers can continue to nurture their children, and grandparents can enjoy watching future generations flourish, Jane Halton, chair of the board for CEPI, said in a press release.

Despite being built and funded from scratch amid the deadliest pandemic the world has seen in more than a century, COVAXs lifesaving accomplishments were considerable. It should take its place in history and be proud of what it was able to accomplish but also serve as a reminder to us all that we can and must do better next time, she said.

COVAX was created to overcome a global imbalance of access to COVID-19 vaccines after they started rolling out in higher income nations like the United States, which re-engaged with WHO and joined the COVAX initiative in January 2021.

The program was designed based on lessons from the H1N1 pandemic, most significantly advocating that no one is safe until everyone is safe, focusing on global vaccine equity for at least people who were at greatest risk for hospitalization or death, with 190 nations joining the effort by the end of 2020.

Of the 146 nations that received COVID-19 vaccine doses from COVAX, 92 lower income nations are eligible to continue receiving doses and delivery support through Gavis regular vaccination programs in 2024 and 2025. According to Gavi, 58 of the 92 nations have already requested roughly 83 million doses to vaccinate various high-risk groups of people.

We knew that market forces alone would not deliver equitable access to vaccines and other tools, WHO Director-General Tedros Adhanom Ghebreyesus, MD, said in a press release. The creation of ACT-A and COVAX gave millions of people around the world access to vaccines, tests, treatments and other tools who would otherwise have missed out. COVAX has taught us valuable lessons that will help us be better prepared for future epidemics and pandemics.

Add topic to email alerts

Receive an email when new articles are posted on

Back to Healio

Original post:

COVAX to end as COVID-19 vaccines move to routine immunization programs - Healio

Pace of COVID deaths slowed in 2023 by toll rose by 1,100 in Wisconsin – Milwaukee Journal Sentinel

January 3, 2024

jsonline.com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use.

Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on jsonline.com

View post:

Pace of COVID deaths slowed in 2023 by toll rose by 1,100 in Wisconsin - Milwaukee Journal Sentinel

Lakeland Regional Health sees COVID-19 and flu cases double over the holidays – WFLA

January 3, 2024

LAKELAND, Fla. (WFLA) Dr. Tim Regan drove to work Tuesday mentally preparing himself for what he knew would be a busy day in the Lakeland Regional Health emergency room.

Right after New Years and theres a lot of respiratory illness in the community, people have now shaken off their holiday and are looking to feel better. So we do see a lot of traffic through the emergency department this time of year, said Dr. Regan, the hospitals Chief Medical Officer.

According to Dr. Regan, patients with COVID-19 and flu have doubled at Lakeland Regional Health, with those cases still making up less than 10% of total hospitalizations.

Most COVID-19 infections now are causing cold-like symptoms, he said, which can be treated with ibuprofen and decongestants.

Patients are also coming in with RSV.

You tend to talk about RSV in children, but elderly people and people who are at risk for illness are at risk for RSV as well and it can have bad outcomes, he said.

Pamela Wood, who lives in Lakeland, said she had a persistent cough and her doctor tried everything to prevent her from getting RSV.

Just had a head cold and normally I can shake them off and this time I didnt, had a bad cough. Went to the doctor and he gave me an antibiotic and steroid shot and meds, she said. When you get 70 years old, you cant shake this stuff off like you could when you were younger.

Jo Hair, a snowbird who winters in Lakeland, said her family had a firsthand experience with severe respiratory illness.

We did have a child in the family up north that was hospitalized with RSV so it brings to light everybody should be paying attention, continue doing what you should be doing, she said.

Luckily, that infant recovered.

Meanwhile, data from the Centers for Disease Control & Prevention shows COVID-19 hospitalizations are low in all Florida counties except for Sarasota, Desoto and Charlotte counties, which are medium.

When it comes to influenza, according to the CDC as of Dec. 23, Florida is at a high level of cases, surrounded by states at a very high level.

That is to be predicted this time of year, with influenza being very seasonal throughout central Florida. Weve seen greater numbers of influenza which sort of correlates to years in the past, said Dr. Jarett Gregory, an urgent care physician at Watson Clinics south campus.

He said it is the combination of cooler weather, people traveling and visiting with family over the holidays and snowbirds coming to Florida that leads to the spike in illness.

Weve certainly seen a higher number of acuity, higher number of cases, certainly quite a bit busier than we have been in the months previous, said Dr. Gregory.

He said the timing of a doctors visit is an important factor when it comes to getting effective treatment.

If a patients had cough, cold, fever or body aches for one to two days, they want to act more promptly rather than waiting. If they can be seen and evaluated over the next 24 to 48 hours treatment and be initiated and often make a big difference and help them to recover much more quickly, said Dr. Gregory.

The rest is here:

Lakeland Regional Health sees COVID-19 and flu cases double over the holidays - WFLA

Communicating COVID-19 – Cosmos

January 3, 2024

It was overwhelming, say immunologist Dr Chris Puliuvea and virologist Dr Natalie Netzler.

TheNew Zealand Association of Scientists(NZAS) had called to say the pair had won New Zealands most coveted science communication prize, the 2023Cranwell Medal,for their community engagement during the COVID-19 pandemic.

It was such a privilege and an honour, Netzler says.

We all remember the dark days of the COVID-19 pandemic the fear and the lockdowns, the loneliness, and perhaps the losses of those we loved. The quiet cities. The variants and the vaccinations. Working from home, the toilet paper wars.

Those days are still raw, and of course, COVID-19 is still with us.

Puliuvea, who is Tongan, was then a PhD candidate at the University of Auckland. Netzler is Mori and Samoan and a senior lecturer also at the University of Auckland. Neither set out to win the prize, they were simply responding to the Mori and Pasifika communities need for unambiguous, factual information on the disease, and on the vaccinations under development. Pasifika communities are people of Pacific ethnic origin living in New Zealand.

By the end of June 2021, both researchershad been fielding COVID-related questions from family and friends in their Pasifika and Mori communities for months. Whats this new vaccine?, Why get vaccinated Is it safe?, What do we do?

New Zealands often-cursed tyranny of distance and government policy were working in the countrys favour by then,there were just 2741 cases,and31 people had succumbed to the disease. Globally, the picture was dire, withabout 180 million cases and almost 4 million deaths.TheUS Food and Drug Administrations approval of the first COVID-19 vaccine Pfizer BioNTech, on 23 August was then still almost two months away.

Then Puliuvea and Netzler received invitations to talk at theInaugural Pacific Peoples Fono(meeting), held In Auckland in June 2021. The conference, hosted by Mori and Pacific Island researchers from the Universities of Auckland and Otago, discussed research into issues affecting Pacific peoples.

Subjects ranged from antimicrobial resistance to drug development, traditional medicines, and COVID-19, with Netzler covering vaccines and PuIiuvea, the immune response. Researchers also focussed on correcting misinformation and disinformation, says Puliuvea. The hall was packed with a broad cross-section of Aucklands Mori and Pacific communities, including community organisations, nurses, midwives, clinicians and doctors.

Puliuvea and Netzler were flooded with questions. Netzler says that the response showed the communitys appetite for answers they were really struggling to find a touch-point that was relatable, where they could get the answers that they needed, she says.

Multiple invitations followed, and more talks were given, at community groups and organisations in Auckland, and online more than 60 events:videos, webinars, Tik Tok and Facebook Lives, reaching into Mori and Pasifika communities in New Zealand, Australia and throughout the Pacific, says Netzler.

The videos, on how vaccines work and getting vaccinated, were created because the pair couldnt keep up with demand, says Puliuvea. Many of the face-to-face and online events were set up by Youth Horizons (Kia Puwai) Pasifika Principal Advisor, Synthia Dash, with the first aimed at Kia Puwais Pasifika and Mori frontline staff, 90% of whom were averse to vaccination.

Dash knew that Netzler and Puliuvea had the necessary cultural competency and humility to sensitively frame the information without stepping on the cultural and religious beliefs holding staff back from vaccination. Proportions reversed after 6 months of work, with 90% taking the needle. What we wanted was to answer specific questions and make sure that people felt like it was a two-way dialogue, so they were empowered, says Netzler. At one of those meetings, she continues, a guy got up and said: Ive never seen a scientist that looks like us, before.

Science is full of jargon converting the language of COVID-19 into understandable English was, and is, a challenge in itself. Translation into meaningful Mori, Tongan, Samoan, Niuean and Tuvaluan, adds further complexity, particularly as there are often no equivalents for the terms needed.

The researchers presentations were translated into these languages through a range of organisations. A partnership with theMokoFoundation delivered the English-Mori translation, and Puliuvea did the Tongan translations. He would often Tonganise a word to make it flow within a sentence in that language. Antibody would become antipoti, lockdown would become lokatauni, so that the Tongan community could relate it to the English word when they came across it, he says. Immune system became sisitemi malui. Malui means to protect.

At one of those meetings, a guy got up and said: Ive never seen a scientist that looks like us, before.

Puliuvea and Netzler also made extensive use of analogies. One of Netzlers favourites involved going to war with the virus, and comparing the vaccination to a fire drill. Antibodies are the weapons, shed say, and the vaccine is like a fire drill, teaching your body how to fight off the virus before it brings the house down. Viruses, like fires, can get away on you, shed continue, and become uncontrollable. If youve had a vaccination, your immune response has been trained and can quickly quench a real infection before it brings the house down.

In addition, Puliuvea says Mori and Pasifika communities are showing a lot of interest in the publication of a dictionary of medical terms in their languages. We dont need to wait for a pandemic for this to happen, he adds. We need medical terms and their Mori and Pasifika translations, to improve communication between communities and local medical professionals.

Some lists do exist already April 2020 saw the release of a list ofMori terms for COVID.

Its not merely the need to understand concepts which drives these communities.

Data are hard to come by, but the New Zealand Medical Journalreportedthat Mori are 2.5 times, and Pasifika 1.8 times, more likely to die of a COVID-19 infection than European New Zealanders.

A variety of issues contribute, includingmultigenerational livingwhich tends to overcrowding because of the lack of suitable housing, andpoverty, which exacerbates access to health care.

We need medical terms and their Mori and Pasifika translations, to improve communication between communities and local medical professionals.

And there may be genetic reasons. The gene, LZTFL1, has been associated witha two-fold increase in respiratoryfailure in COVID patients. A variant of this gene causes shorter villi in the upper respiratory tract in some Southeast Asian populations, which means that the virus spreads more easily into the body, resulting in severe disease, says Puliuvea.

That gene is slightly different in Mori and Pacific people, and Puliuvea is currently exploring linkages with disease. If the variant is associated with severe illness, we can prioritise carriers for vaccination, he says. We detected more than 2000 unique genetic variants in Mori and Pasifika people, that were virtually absent in other populations. Some of these unique variants occurred in up to 30% of the people sampled, he adds.

Puliuvea and Netzler continue to drive health literacy and empower Mori and Pasifika communities. As Netzler said, Chris and I were really honoured with this medal, but there was such a group effort, involving a lot of partnering with a lot of people, including churches, charities, schools, and other organisations.

Visit link:

Communicating COVID-19 - Cosmos

Predicting COVID-19 variant waves with AI – EurekAlert

January 3, 2024

image:

Jaccard distance Jd between dominant SARS-CoV-2 variants in the United Kingdom.

Credit: Levi et al

An AI model can predict which SARS-CoV-2 variants are likely to cause new waves of infection. Current models used to predict the dynamics of viral transmission do not predict variant-specific spread. Retsef Levi and colleaguesstudied what factors could shape the viral spread based on analysisof 9 million SARS-CoV-2 genetic sequences collected by the Global Initiative on Sharing Avian Influenza Data (GISAID) from 30 countries, along with data on vaccination rates, infection rates, and other factors. The patterns that emerged from this analysis were used to build a machine-learning enabled risk assessment model. The model can detect 72.8% of the variantsin each countrythat will cause at least1,000 cases per million peoplein the next three months after an observation period of only one week after detection.This predictive performance increases to 80.1% after two weeks of observation. Among the strongest predictorsthat a variant will become infectious are the early trajectory of the infections caused by the variant, the variants spike mutations, and how different the mutations of a new variant are from those of the most dominant variant during the observation period. The modeling approach could potentially be extendedto predict the future course of other infectious diseases as well, according to the authors.

Predicting the spread of SARS-CoV-2 variants: An artificial intelligence enabled early detection

2-Jan-2024

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

View original post here:

Predicting COVID-19 variant waves with AI - EurekAlert

Page 36«..1020..35363738..5060..»